tradingkey.logo
tradingkey.logo
Search

Gain Therapeutics Inc

GANX
Add to Watchlist
1.680USD
-0.080-4.55%
Close 07-31 16:00ETQuotes delayed by 15 min
71.38MMarket Cap
LossP/E TTM

GANX Income Statement

You can find the annual or quarterly income statement of Gain Therapeutics Inc here for insights into the performance and operational efficiency of Gain Therapeutics Inc.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
FY2021Q1
FY2020Q2
FY2020Q1
Total revenue
----
----
----
----
----
--0.00
--0.00
--0.00
-100.00%0.00
--0.00
--0.00
-100.00%0.00
22.61%55.18K
-100.00%0.00
-100.00%0.00
6.65%95.10K
754.17%45.01K
--43.21K
--27.34K
1299.23%89.17K
-21.04%5.27K
--6.37K
--6.67K
Revenue
----
----
----
----
----
----
--0.00
--0.00
-100.00%0.00
--0.00
--0.00
-100.00%0.00
22.61%55.18K
-100.00%0.00
-100.00%0.00
6.65%95.10K
754.17%45.01K
--43.21K
--27.34K
1299.23%89.17K
-21.04%5.27K
--6.37K
--6.67K
Operating expenses
22.52%5.35M
34.07%4.47M
7.33%4.79M
-37.80%5.09M
-0.19%4.37M
-24.42%3.33M
-8.72%4.46M
5.84%8.18M
-17.17%4.38M
-3.38%4.41M
2.82%4.89M
46.66%7.73M
58.54%5.28M
40.26%4.56M
1.88%4.75M
46.28%5.27M
34.84%3.33M
--3.25M
--4.66M
568.80%3.60M
376.40%2.47M
--538.84K
--518.93K
R&D expenses
23.32%2.74M
94.59%2.32M
8.71%2.81M
-38.17%2.72M
-10.04%2.22M
-49.86%1.19M
9.24%2.59M
10.40%4.40M
-11.47%2.47M
4.40%2.37M
20.50%2.37M
54.44%3.99M
79.33%2.79M
54.42%2.27M
-20.67%1.96M
43.98%2.58M
9.49%1.56M
--1.47M
--2.48M
308.67%1.79M
240.68%1.42M
--438.87K
--417.26K
Depreciation, depletion, and amortization
3.11%21.30K
31.82%29.00K
0.00%22.00K
4.76%22.00K
0.64%20.66K
-6.74%22.00K
7.27%22.00K
3.76%21.00K
6.68%20.53K
30.25%23.59K
15.04%20.51K
1.09%20.24K
134.40%19.24K
212.89%18.11K
330.84%17.83K
827.76%20.02K
141.23%8.21K
--5.79K
--4.14K
-5.18%2.16K
61.97%3.40K
--2.28K
--2.10K
Operating profit
-22.52%-5.35M
-34.07%-4.47M
-7.33%-4.79M
37.80%-5.09M
0.19%-4.37M
24.42%-3.33M
8.72%-4.46M
-5.84%-8.18M
16.29%-4.38M
3.38%-4.41M
-2.82%-4.89M
-49.35%-7.73M
-59.03%-5.23M
-42.15%-4.56M
-2.48%-4.75M
-47.28%-5.18M
-33.30%-3.29M
---3.21M
---4.64M
-560.06%-3.51M
-381.57%-2.47M
---532.47K
---512.26K
Net non-operating interest income (expenses)
Gains from sale of securities
-64.21%-165.17K
-638.02%-84.78K
77.40%-27.38K
-1324.92%-620.92K
-137.52%-100.59K
103.86%15.76K
-247.37%-121.14K
27.61%-43.58K
725.73%268.08K
-105.34%-408.51K
89.00%82.20K
-249.69%-60.20K
-323.58%-42.84K
-911.13%-198.94K
258.66%43.49K
190.63%40.21K
3.36%19.16K
---19.68K
---27.41K
-813.55%-44.37K
126.90%18.54K
---4.86K
---68.91K
Income before tax
-22.49%-5.43M
-36.89%-4.47M
-5.82%-4.74M
30.39%-5.67M
-10.90%-4.43M
30.70%-3.26M
4.73%-4.47M
-6.27%-8.14M
21.99%-3.99M
-2.46%-4.71M
-3.13%-4.70M
-50.93%-7.66M
-56.55%-5.12M
-42.38%-4.60M
2.24%-4.55M
-42.87%-5.08M
-33.67%-3.27M
---3.23M
---4.66M
-559.39%-3.55M
-319.78%-2.45M
---538.84K
---582.92K
Income tax
82.14%183.07K
-86.11%70.12K
4896.25%549.29K
11579.49%141.21K
405.73%100.51K
3380.47%504.74K
-48.76%10.99K
-95.45%1.21K
18.81%19.87K
-81.43%14.50K
430.04%21.46K
190.72%26.59K
897.50%16.73K
1047.42%78.11K
-20.84%4.05K
149.89%9.15K
-51.80%1.68K
---8.24K
--5.11K
-19.08%3.66K
158.28%3.48K
--4.52K
--1.35K
Income after tax
-23.81%-5.61M
-20.42%-4.54M
-17.81%-5.28M
28.66%-5.81M
-12.85%-4.53M
20.23%-3.77M
4.93%-4.49M
-5.92%-8.14M
21.86%-4.01M
-1.06%-4.72M
-3.51%-4.72M
-51.18%-7.69M
-56.98%-5.14M
-45.17%-4.67M
2.26%-4.56M
-42.98%-5.09M
-33.55%-3.27M
---3.22M
---4.66M
-554.57%-3.56M
-319.40%-2.45M
---543.36K
---584.27K
Net income from continuous operations
-23.81%-5.61M
-20.42%-4.54M
-17.81%-5.28M
28.66%-5.81M
-12.85%-4.53M
20.23%-3.77M
4.93%-4.49M
-5.92%-8.14M
21.86%-4.01M
-1.06%-4.72M
-3.51%-4.72M
-51.18%-7.69M
-56.98%-5.14M
-45.17%-4.67M
2.26%-4.56M
-42.98%-5.09M
-33.55%-3.27M
---3.22M
---4.66M
-554.57%-3.56M
-319.40%-2.45M
---543.36K
---584.27K
Other net gains and losses
----
--3.51K
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Net income attributable to controlling interests
-23.81%-5.61M
-20.42%-4.54M
-17.81%-5.28M
28.66%-5.81M
-12.85%-4.53M
20.23%-3.77M
4.93%-4.49M
-5.92%-8.14M
21.86%-4.01M
-1.06%-4.72M
-3.51%-4.72M
-51.18%-7.69M
-56.98%-5.14M
-45.17%-4.67M
2.26%-4.56M
-42.98%-5.09M
-33.55%-3.27M
---3.22M
---4.66M
-554.57%-3.56M
-319.40%-2.45M
---543.36K
---584.27K
Net income attributable to common shareholders
-23.81%-5.61M
-20.42%-4.54M
-17.81%-5.28M
28.66%-5.81M
-12.85%-4.53M
20.23%-3.77M
4.93%-4.49M
-5.92%-8.14M
21.86%-4.01M
-1.06%-4.72M
-3.51%-4.72M
-51.18%-7.69M
-56.98%-5.14M
-45.17%-4.67M
2.26%-4.56M
-42.98%-5.09M
-33.55%-3.27M
---3.22M
---4.66M
-554.57%-3.56M
-319.40%-2.45M
---543.36K
---584.27K
Basic earnings per share
15.90%-0.13
11.79%-0.12
10.69%-0.15
54.82%-0.19
29.27%-0.16
56.76%-0.14
54.49%-0.17
31.72%-0.42
48.13%-0.22
20.04%-0.31
3.15%-0.37
-45.03%-0.62
-56.30%-0.43
-45.38%-0.39
2.31%-0.38
-42.90%-0.43
-33.48%-0.28
---0.27
---0.39
-524.55%-0.30
-300.17%-0.21
---0.05
---0.05
Diluted earnings per share
15.90%-0.13
11.79%-0.12
10.69%-0.15
54.82%-0.19
29.27%-0.16
56.76%-0.14
54.49%-0.17
31.72%-0.42
48.13%-0.22
20.04%-0.31
3.15%-0.37
-45.03%-0.62
-56.30%-0.43
-45.38%-0.39
2.31%-0.38
-42.90%-0.43
-33.48%-0.28
---0.27
---0.39
-524.55%-0.30
-300.17%-0.21
---0.05
---0.05
Dividend per share
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----

FAQs

How do I read Gain Therapeutics Inc's income statement on TradingKey?

Start with total revenue, then review cost of revenue, gross profit, operating expenses, operating profit, income before tax, net income, and EPS. Revenue shows the scale of the business, while margins and profit lines show whether that revenue is being converted into earnings efficiently.

What is the difference between quarterly and annual income statements?

A quarterly income statement shows performance for a three-month fiscal period, while an annual income statement summarizes the full fiscal year. Quarterly data is useful for tracking recent momentum and seasonality, while annual data is better for judging long-term growth, profitability, and business cycles.

What does YOY mean on the income statement page?

YOY means year over year. It compares a financial metric with the same period in the previous year, such as this quarter's revenue versus revenue in the same quarter last year. YOY comparison helps investors see growth trends while reducing the impact of normal seasonal changes.

Which income statement metrics matter most when analyzing GANX stock?

Important metrics include revenue growth, gross profit, gross margin, operating profit, operating margin, net income, EPS, R&D expenses, SG&A expenses, and tax expense. Investors usually look at these together to judge whether the company is growing, controlling costs, and improving profitability.

What was Gain Therapeutics Inc's net income for the year?

Gain Therapeutics Inc posted -20.16M in net income for fiscal year 2025.

How much net income did Gain Therapeutics Inc post in the last quarter?

Gain Therapeutics Inc reported -5.61M in net income for the latest quarter。

What was Gain Therapeutics Inc's annual operating profit?

Gain Therapeutics Inc's operating income was -18.71M for fiscal year 2025.

How is EPS related to the income statement?

EPS, or earnings per share, is based on net income divided by the number of shares outstanding. It helps investors understand how much profit the company generated for each share, but it should be reviewed alongside share count changes, margins, cash flow, and valuation metrics.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.